The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis research problem. What makes a good research study, anyway?

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

CannaMD

NOVEMBER 4, 2020

According to a recent study published in the Journal of Headache Pain , across 2,032 patients and 21 illnesses, headache was a symptom treated with cannabis in 24.9% (505) of cases, while 88% (445) of headache patients treated probable migraines with cannabis. 30 percent of migraine patients in the U.S. Other Research Findings.

Patients 105

Patients Chronic Pain Marijuana Research and Development 105

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.

Data 100

Data Research and Development Patients Strains 100

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JULY 29, 2021

Ben Kaplan, CEO of Ehave, said, “We strongly believe there is a genetic predisposition to this condition and will be conducting a large-scale genetic analysis to isolate an individuals’ risk profile. Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question.

Research and Development 105

Research and Development Conditions Data Patients 105

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

SpeedWeed

MARCH 14, 2021

Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.

Data 52

Data Research and Development Marijuana Collective 52

Veriheal

NOVEMBER 13, 2020

Until recently, there has been little to no research available that examines the effects of cannabis in patients diagnosed with Obsessive-Compulsive Disorder (OCD). Many patients with OCD tend to perform actions without wanting to, but feeling powerless to try and stop it. What Does Research Say About Cannabis and OCD?

Research and Development 98

Research and Development Consumption Patients Strains 98

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. This latest partnership further strengthens Beckley Psytech’s digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. Acumen Research and Consulting confirmed TNF-? President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Veriheal

FEBRUARY 9, 2023

Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. While comfy MRIs are not its primary goal, this psychedelic research has provided solid preliminary evidence that the psychoactive compound found in magic mushrooms can help accomplish just that.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. . – December 16, 2021) – Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. This process involves various stages, including cultivation, processing, packaging, distribution, and retailing.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Veriheal

NOVEMBER 21, 2023

Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy. Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments.

Research and Development 106

Research and Development Consumption Education Data 106

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 14, 2019

Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Big Data Improves Distribution in the Marijuana Industry. Source: [link]. Global Cannabis Applications Corp.

Data 45

Data Research and Development Marijuana Collective 45

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. So, why did this educational gap develop? Unfortunately, this did not occur.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Project CBD

JANUARY 24, 2019

Published in Nature , the study found that just under a third of patients report significant improvements and over half report moderate improvements while using CBD -rich oil derived from cannabis (30% CBD , 1-2% THC ). Previous research has found that THC may be effective for some cases that do not respond well to Ritalin. .

Research and Development 252

Research and Development Chronic Pain Cannabinoids Treatment 252

Greencamp

AUGUST 16, 2018

In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Both upper and lower motor neurons suffer severe damage in ALS patients. Let’s explore this in more detail. What exactly is ALS?

Strains 94

Strains Cannabinoids Research and Development Indica 94

The Cannigma

MARCH 14, 2023

And the truth was that many of the early medical cannabis patients were severely ill. Cancer, HIV, epilepsy and other serious conditions were the first accepted uses of cannabis in the United States. Many of the early medical cannabis states had strict lists of conditions for which cannabis could be legally used.

Policy 96

Policy Research and Development Conditions Consumption 96

Veriheal

AUGUST 15, 2022

This is according to a group of researchers from the University of New Mexico (UNM) , who recently teamed up with the creators of the Releaf App to investigate the true link between cannabis use and energy levels. The condition may also occur as a result of poor lifestyle habits, chronic disease, and depression.

Treatment 96

Treatment Research and Development Sativa Cannabinoids 96

Cannabis Law Report

JULY 25, 2022

together with research collaborators at the University of Auckland , have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD).

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

PrestoDoctor

SEPTEMBER 6, 2023

Traditionally, prescription codeine has been prescribed for a variety of conditions, including post-operative pain, dental procedures, and chronic pain. It has been a go-to option for healthcare professionals seeking to manage pain effectively for their patients. This has led them to seek out alternative options like cannabis.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

JUNE 29, 2021

Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. Ehave, Inc. Forward-Looking Statement Disclaimer.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Veriheal

DECEMBER 23, 2022

Researchers Inspected Cannabis Products for Contaminants. Dr. Maxwell’s team also collected data contained in samples sourced from California. There was more inconsistency in cannabis-borne contaminant regulation as compared with other agricultural commodities,” wrote the researchers. As per the results, 2.3% for extracts.

Research and Development 92

Research and Development Agriculture Data Extraction 92